Publications by authors named "Mitsuhiro Shikamura"

Claim this Profile
T
Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study.
Kouji Masumoto, Mitsuru Muto, Takato Sasaki, Mitsuhiro Shikamura, Tomoko Tanaka

Pediatr Int· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temporal risk patterns of severe hypovolemia associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: A self-controlled case series study.
Mitsuhiro Shikamura, Atsushi Takayama, Kasumi Yokogawa, Koji Kawakami

Diabetes Obes Metab· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A retrospective nationwide claims database study in Japan.
Mitsuhiro Shikamura, Atsushi Takayama, Masato Takeuchi, Koji Kawakami

Diabetes Obes Metab· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis.
Makoto Naganuma, Kenji Watanabe, Satoshi Motoya, Haruhiko Ogata, Toshiyuki Matsui, Mitsuhiro Shikamura

J Gastroenterol Hepatol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis.
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Mitsuhiro Shikamura

Intest Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial.
Masakazu Nagahori, Kenji Watanabe, Satoshi Motoya, Haruhiko Ogata, Takanori Kanai, Mitsuhiro Shikamura

Digestion· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses.
Kenji Watanabe, Satoshi Motoya, Haruhiko Ogata, Takanori Kanai, Toshiyuki Matsui, Mitsuhiro Shikamura

J Gastroenterol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
Satoshi Motoya, Kenji Watanabe, Haruhiko Ogata, Takanori Kanai, Toshiyuki Matsui, Mitsuhiro Shikamura

PLoS One· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
Satoshi Motoya, Kenji Watanabe, Haruhiko Ogata, Takanori Kanai, Toshiyuki Matsui, Mitsuhiro Shikamura

PLoS One· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis